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Abstract
The genes PRKACA and PRKACB encode the principal catalytic (C) subunits of protein kinase A (PKA) Ca and Cb, respectively.
Ca is expressed in all eukaryotic tissues examined and studies of Ca knockout mice demonstrate a crucial role for Ca in
normal physiology. We have sequenced exon 2 through 10 of PRKACA from the genome of 498 Norwegian donors and
extracted information about PRKACA mutations from public databases. We identified four interesting nonsynonymous point
mutations, Arg45Gln, Ser109Pro, Gly186Val, and Ser263Cys, in the Ca1 splice variant of the kinase. Ca variants harboring the
different amino acid mutations were analyzed for kinase activity and regulatory (R) subunit binding. Whereas mutation of
residues 45 and 263 did not alter catalytic activity or R subunit binding, mutation of Ser109 significantly reduced kinase
activity while R subunit binding was unaltered. Mutation of Ca Gly186 completely abrogated kinase activity and PKA type I
but not type II holoenzyme formation. Gly186 is located in the highly conserved DFG motif of Ca and mutation of this
residue to Val was predicted to result in loss of binding of ATP and Mg
2+, which may explain the kinetic inactivity. We
hypothesize that individuals born with mutations of Ser109 or Gly186 may be faced with abnormal development and possibly
severe disease.
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Introduction
Protein Kinase A (PKA) is a cyclic AMP (cAMP)-dependent
Ser/Thr kinase involved in regulating a multitude of biological
processes including cell growth and division, cell differentiation, as
well as metabolism and immune responsiveness [1]. In its inactive
state, PKA exists as a tetrameric holoenzyme consisting of two
regulatory (R) and two catalytic (C) subunits. Four different genes,
PRKAR1A, PRKAR1B, PRKAR2A, and PRKAR2B, encode the R
subunit proteins RIa,R I b, RIIa, and RIIb, respectively, with
several splice variants of the RIa and RIIa subunits [2,3]. Two
principal genes, PRKACA and PRKACB, encode the C subunits Ca
and Cb, respectively. Also, PRKX and the retroposons PRKY and
PRKACG are identified as PKA C subunit genes. While no protein
products for PRKY and PRKACG have been identified, PRKX is
translated into a protein kinase which is inhibited by the R subunit
in a cAMP-sensitive manner [4–7]. Both the PRKACA and
PRKACB genes encode several protein products. Alternative use
of two exons upstream of exon 2 in the PRKACA gene gives rise to
two Ca variants with different N-termini. These proteins are
designated Ca1 and Ca2 [8–11]. In the case of the PRKACB gene,
several exons 59 of exon 2 are encoding a number of Cb splice
variants designated Cb1, Cb2, Cb3, and Cb4 [12,13], as well as a
number of Cb3 and Cb4 forms that contain N-terminal inserts
from exons designated a, b, and c [14,15]. In the brain and
nervous tissues of higher primates, a range of C variants lacking
exon 4 encoded sequences are also identified [16].
The two major groups of the R subunits RI and RII form two
types of the PKA holoenzymes termed PKA type I and PKA type
II, respectively. The C subunits are the catalytically active
components, and they become activated after dissociation from
the R subunits in a cAMP-dependent manner. For specificity in
the cAMP-PKA signaling pathway, the PKA holoenzymes can be
located to specific subcellular structures via A Kinase Anchoring
Proteins (AKAPs). AKAPs typically bind RII subunits with high
affinity [8,17–19]. In contrast, PKA type I holoenzymes tend to
locate to the soluble fraction of the cell but can bind to dual- and
RI-specific AKAPs [19]. Both the C and R subunits are
differentially expressed in various tissues. Whereas Ca1i s
ubiquitously expressed, Ca2 is exclusively found in sperm cells
[8–10]. For the Cb variants, Cb1 is ubiquitously expressed, while
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tissues, such as lymphoid and neuronal tissues [14,15].
Ca1 is the principal source of PKA activity in most tissues [11]
and was the first protein kinase to be subjected to crystallization
and 3D structure determination [20]. The Ca1 structure reveals a
large C terminal lobe (C-lobe or large lobe) and a smaller N
terminal lobe (N-lobe or small lobe). The large lobe is mainly
composed of a-helices, and is involved in R subunit and substrate
binding. It contains a number of residues involved in catalysis. The
small lobe is mostly composed of b-strands and contains an ATP
binding site. Between the large and small lobe is the active site
cleft. The small and large lobes, as well as the active site, are
known as the catalytic core and are encoded by residues 40–300 in
PKA Ca1. The amino acid sequence and 3D structure of the
catalytic core are conserved among all protein kinases. The
catalytic core may, in addition to ATP, bind two Mg
2+ ions that
are critical for catalysis [20]. The two Mg
2+ ions are designated
activating and inhibitory Mg
2+, or Mg1 and Mg2, respectively
[21]. The binding affinity for Mg1 is higher than for Mg2 in the
presence of ATP, while binding of Mg2 is believed to stabilize the
protein, but also to inhibit catalysis [21–24]. Mg
2+ is also essential
for high-affinity binding to inhibitors PKI and RIa subunits [25].
For catalytic activity, Ca has to be phosphorylated on residue
Thr197, located in the activation loop of the large lobe. This
phosphorylation affects the conformation of the conserved DFG
(Asp184-Phe-Gly) motif in the active site [26]. In the active
conformation, Asp184 of the DFG motif coordinates the three
phosphates of ATP via the Mg
2+ ions, positioning the c-phosphate
of ATP optimally for catalysis. This central role of Asp184 in
catalysis depends on a conserved hydrogen bond between Asp184
and Gly186 backbone amide group. This interaction orients Asp184
perfectly for coordination of the Mg
2+ ions and efficient ATP
binding [27]. The Asp184-Gly186 hydrogen bond is only estab-
lished after phosphorylation of Thr197, which causes a twist of the
peptide bond between Phe185 and Gly186. In this way phosphor-
ylation of Thr197 serves as a regulatory mechanism for the
activation of the C subunit. The Local Spatial Pattern (LSP)
alignment method, developed by Kornev et al [27], has revealed
two conserved spatial motifs in eukaryotic protein kinases. These
are two hydrophobic structures called the Catalytic (C-) and
Regulatory (R-) spines that have to be established in order for the
kinase to become catalytically active. The C-spine is completed
when the adenine nucleobase of ATP interacts with the active site.
For the R-spine to be established, Thr197 in the activation loop has
to be phosphorylated. Evaluation of the C- and R-spines is a
helpful way of predicting whether a kinase has a catalytically active
or inactive conformation.
Despite its central role in a multitude of processes in the body,
few diseases have been linked to defects or alterations in the PKA
subunit genes or proteins. Germline mutations leading to
premature stop codons in PRKAR1A have been identified in
patients with Carney complex, a multiple neoplasia syndrome with
skin pigmentations, cardiac and other myxomas, endocrine
tumors, and psammomatous melanotic schwannomas [28,29].
To the best of our knowledge, no diseases have been linked to
defects in any of the C subunit genes. Nevertheless, studies on mice
that are homozygote knockout (KO) for the PRKACA gene reveal a
severe phenotype. The majority of the Ca
2/2 mice die at birth or
during the early postnatal period [30]. The offspring that survive
beyond 2 months (, 11%, [31]), all show reduced growth, and the
few males, but not females, that reach puberty are all 100%
infertile [30,32]. Furthermore, mice with reduced PKA C gene
transcription by only expressing one functional C subunit allele of
Ca or Cb, show reduced PKA activity and neural tube defects
[33].
Due to the severe phenotype of Ca KO mice we searched for
mutations in the human PRKACA gene by genomic sequencing of
498 subjects. We identified two nonsynonymous point mutations
in the PRKACA gene that result in amino acid switches in the Ca1
protein at residues 45 and 109. In addition, we searched for
previously described nonsynonymous mutations in various human
genomic DNA databases, and selected two of these, giving amino
acid switches at residues 186 and 263, for further studies. These
four mutations were introduced to Ca1- and Ca2-encoding
plasmids and the proteins were expressed and analyzed with
respect to kinase activities and R subunit binding in vitro and in vivo.
Mutation of residues 109 and 186 were associated with
significantly reduced and totally abrogated kinase activity,
respectively. In addition, mutation of residue 186 rendered Ca
incapable of forming PKA type I holoenzymes.
Materials and Methods
Analysis of Mutations
The PRKACA gene from 498 Norwegian donors deriving from
three different control groups [34,35] was sequenced and analyzed
for point mutations by Lark Technologies (Takeley, UK).
Leukocyte DNA was isolated from thawed blood containing
ethylenediaminetetraacetic acid. Using the Applied Biosystems
340A Nucleic Acid Extractor, DNA was extracted with chloro-
form/phenol followed by ethanol precipitation. Exons 2–10 of
PRKACA were sequenced using the primers listed in table 1.
A search for mutations in the PRKACA gene was also performed
in the following public databases: NCBIs dbSNP [36,37], Ensembl
[38], and SNPper [39].
Generation of Plasmids
The pDONR201-Ca1WT vector has previously been described
[40] and was used to make plasmids containing Ca1Mut using
QuikChangeH II Site-Directed Mutagenesis Kit (Stratagene, cat.
no. 200524) according to the manufacturer’s protocol. The
pDONR201-Ca1 variants were transferred to the eukaryotic
Table 1. Primers used for sequencing of PRKACA exons 2 to
10.
Sequencing of exon no. Primers
2 Forward: 59-AGGCTCTGGGTTGGAACTGC-39
2 Reverse: 59-CTGGCATTGGGCAGTCAGGT-39
3 Forward: 59-GCCTTAAGGAATGTGCCCTC-39
3 Reverse: 59-TGGCGAAAACCCATCTCTAC-39
4 Forward: 59-CCACGGCTCTGACCTCTGTG-39
4 Reverse: 59-GATGTTACTGAGGTTGGGTG-39
5 Forward: 59-CTCAAGCTCCCAGAGCAAGG-39
5 Reverse: 59-TACTGGTGAGAACCACCGTG-39
6–8 Forward: 59-AATGCAGCCACATTGTTGAG-39
6–8 Reverse: 59-TTGAGGTGTTGGCCTCAGTG-39
9 Forward: 59-ACGTAGTGAGACCCTGTCTC-39
9 Reverse: 59-CGAAACTCTTAATGTAGCAACTC-39
10 Forward: 59-AGTGGTTTGCCACAACTGAC-39
10 Reverse: 59-AGCTGGTGTTTCTGTCCCTC-39
doi:10.1371/journal.pone.0034838.t001
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(Invitrogen, cat. no. 11791–019) according to the manufacturer’s
protocol.
Ca1WT and Ca2WT prokaryotic expression vectors are
previously described [41]. Using QuikChange
TM Site-Directed
Mutagenesis Kit (Stratagene, cat. no. 200518), Ca2WT was
mutated into Ca2Gly186Val.
Ca1 was cloned into the mammalian expression vector pGFP
2-
C3 (Perkin Elmer) as previously described [42], creating the
BRET sensor construct GFP-Ca1WT. Using QuikchangeH II Site-
Directed Mutagenesis Kit, GFP-Ca1WT was mutated into GFP-
Ca1Mut, according to the manufacturer’s protocol. RIa-Rluc and
RIIa-Rluc constructs have previously been described [42].
For all mutagenesis reactions, the PCR reaction mixture was
initially heated to 95uC for 30 s, followed by 16 cycles of 95uC for
30 s, 55uC for 1 min and 68uC for 7 min, before final elongation
at 68uC for 2 min. Primers are listed in table 2. All plasmids were
verified by sequencing (Eurofins MWG Operon).
Purification of Proteins
Ca1WT and Ca2WT were purified by affinity chromatography
using PKI-peptide Affi-Gel, as previously described [41]. Ca2-
Gly186Val was purified using a modified method described by
Hemmer et al [43]. Briefly, BL21(DE3) cells transformed with
either Ca2Gly186Val or His-tagged RIIaGly337Glu (provided by Antje
Badel, University of Kassel, Germany) were cultured and protein
expression induced with IPTG. After centrifugation, the bacterial
pellets were resuspended and lysed, and the lysates were mixed in
equimolar amounts forming PKA holoenzymes. The holoenzymes
were then coupled to a Ni
2+-resin binding the His-tagged R
subunits. Following washing with 50 mM NaH2PO4 (pH 8.0),
5m Mb-mercaptoethanol, and 25 mM KCl, Ca2Gly186Val was
eluted with the same buffer supplemented with 10 mM cAMP.
Cell Cultures and Transfection Methods
HEK 293T cells (ATTC, cat. no. CRL-11268) were cultured at
37uC in humidified air with 5% CO2 in RPMI 1640 (Sigma-
Aldrich, cat. no. R0883) supplemented with 10% fetal bovine
serum (Sigma-Aldrich, cat. no. F7524), 1% non-essential amino
acids (GibcoBRL, cat. no. 11140–035), 1% L-glutamine (Sigma-
Aldrich, cat. no. G7513), sodium pyruvate (GibcoBRL, cat.
no. 11360–039) and 1% Penicillin-Streptomycin solution (Sigma-
Aldrich, cat. no. P4458). The 293T cells were transfected with
Lipofectamine 2000 (Invitrogen, cat. no. 11668–019) according to
the manufacturer’s instructions.
COS-7 cells (ATCC, cat. no. CRL-1651) were cultivated in
Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich),
with 10% (v/v) fetal calf serum (FCSgold, PAA, Coelbe, Germany)
at 37uC and 5% CO2. Cells were split in a 1:3 ratio every 3–4 days
and transfected using PEi (Polysciences, 25 kDa linear polyethy-
lenimine) [44]. Cells were transfected as previously described [42].
Briefly, 2610
4 COS-7 cells were seeded in each well of a 96-well
microplate (Nunclon Surface, cat. no. 136101). After 24 h, cells
were transfected with plasmid DNA (0,2 mg per well) using PEi.
Phosphotransferase Assay
20 h post transfection, the HEK 293T cells were harvested and
washed 3 x in phosphate buffered saline, then lysed in a
potassium-phosphate buffer (5 mM K2HPO4, 1 mM EDTA,
250 mM sucrose and 0.5% Triton X-100, 1 mM phenylmetha-
nesulfonyl fluoride, 1 mM Na3VO4 and protease inhibitor cocktail
(Sigma-Aldrich, cat. no. P8340)) by vortexing and 20 min on ice.
Debris was pelleted by centrifugation at 16 000 g for 15 min at
4uC. After Bradford protein determination (Bio-Rad, cat. no. 500–
0006), all samples were adjusted to equal concentrations.
Phosphotransferase activities of lysates from Ca1WT,C a1Mut,
and mock transfected cells were determined by the phosphotrans-
ferase assay described by Witt and Roskoski [45,46]. Briefly,
phosphotransferase activity against the PKA-specific substrate
Kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly, Sigma-Aldrich) was
measured in a reaction mixture (14.3 mM Mg-acetate, 143 mM
ATP, 7.5 mCi/mL c
232P-ATP (PerkinElmer), 50 mM Tris-HCl,
pH 7.4) in the presence or absence of cAMP or PKI. After
incubation at 30uC for 9 min, the reactions were stopped by
spotting onto p81 phosphocellulose papers followed by 4615 min
washing in 75 mM phosphorous acid. The filter papers were
washed in 96% ethanol for 10 min and air dryed for approxi-
mately 1 h. Phosphotransferase activity was measured by liquid
scintillation in 3 ml Opti-fluor (Packard BioScience, PerkinElmer).
All experiments were repeated at least three times.
BRET Assay
48 h post transfection cells were washed with 1 6 PBS and
BRET read-out was performed by addition of 5 mM of the
luciferase substrate coelenterazine 400 a (Biotrend, Cologne,
Germany). After simultaneous detection of RLuc (410 nm) and
GFP
2 (515 nm) emission by a multi-label reader (POLARstar,
Omega, BMG Labtech GmbH, Ortenberg, Germany) the
ratiometric BRET signal was calculated as followed [emis-
sion515 nm - (not transfected) COS-7 cells515 nm]/[emission410 nm-
(not transfected) COS-7 cells410 nm] using the GraphPad Prism 4
software (La Jolla, CA, USA). Experiments were performed both
in absence and presence of 50 mM forskolin (fsk) and 100 mM3 -
Table 2. Primers for mutagenesis (mutated nucleotide in bold).
Desired mutation Primers
Arg45Gln Forward: 59- CTTGGATCAGTTTGAACAAATCAAGACCCTCGGC-39
Arg45Gln Reverse: 59-GCCGAGGGTCTTGATTTGTTCAAACTGATCCAAG-39
Ser109Pro Forward: 59-CGTCAAACTCGAGTTCCCCTTCAAGGACAACTC-39
Ser109Pro Reverse: 59-GAGTTGTCCTTGAAGGGGAACTCGAGTTTGACG-39
Gly186Val Forward: 59-GGTGACAGACTTCGTTTTCGCCAAGCGCG-39
Gly186Val Reverse: 59-CGCGCTTGGCGAAAACGAAGTCTGTCACC-39
Ser263Cys Forward: 59-CCTTCCCACTTCAGCTGTGACTTGAAGGACC-39
Ser263Cys Reverse: 59-GGTCCTTCAAGTCACAGCTGAAGTGGGAAGG-39
doi:10.1371/journal.pone.0034838.t002
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ments were repeated at least three times.
Immunoblotting
Samples used in phosphotransferase assays were evaluated for C
subunit expression. Protein concentrations of each sample within
an assay were adjusted to the same levels, as described above.
Proteins were separated by SDS-PAGE and transferred to PVDF
membranes. The membranes were blocked by drying and
rehydrated in methanol before incubation with primary antibody
Purified Mouse Anti-PKA [C] (1:250 dilution, BD Transduction
Laboratories, cat. no. 610981) for 1 h, followed by washing with
TBST. After 30 min incubation with secondary antibody HRP
conjugated goat anti-mouse (1:2000 dilution, ICN Biomed, cat.
no. 55563) and washing, proteins were detected by enhanced
chemiluminescence (Pierce Biotechnology, Rockford, IL, USA)
and the Syngene G:BOX imaging system.
Expression of endogenous C and GFP-C constructs in
transfected COS-7 cells used for BRET assays were also assessed
with immunoblotting. Proteins were detected similarly to the
method described above, with the following modifications:
blocking was performed with 5% milk powder for 1 h; primary
antibody was rabbit anti-Ca (Santa Cruz, PKA cat (c-20) cat.
no. SC-903) and secondary antibody anti-rabbit IgG (peroxidase-
linked species-specific whole antibody (ECL) NA934, GE Health-
care, Freiburg, Germany).
Spectrophotometric Kinase Activity Assay
Kinetic activities of purified Ca2WT and Ca2Gly186Val were
evaluated by the continuous enzyme-linked spectrophotometric
method described by Cook et al. [22]. Activities were reported in
U/mg, defined as mmolmg
21min
21. All experiments were
repeated at least three times.
Molecular Representation and Simulation
Selected motifs, including the DFG motif and it’s interactions
with ATP and divalent cations were presented and analyzed with
PyMOL [47], using the experimental structure described by
Thompson et al [48] (PDB identifier 3FJQ). Simulated mutagen-
esis in PyMOL was performed on Gly186 in the DFG motif.
Relevant distances between the Gly186/Val186 residue and
surrounding atoms were calculated.
Results
We performed two independent studies of the PRKACA gene; 1)
by sequencing genomic DNA from 498 Norwegian subjects and 2)
by a bioinformatics analysis of DNA sequences from various
populations submitted to publicly available databases (see Material
and Methods). By the first approach, exons 2 through 10 of
PRKACA were sequenced using exon-specific primers and genomic
DNA extracted from leukocytes. In this way we detected five
mutations in the PRKACA gene; one in each of exons 2, 3, 4, 5, and
8. Only two of the mutations translated into an amino acid switch.
The corresponding nucleotides were located in exons 3 and 4, and
are affecting Arg45 and Ser109 in the Ca1 sequence, while the
three silent mutations were at Pro33, Gly126, and Pro236 (Table 3,
Fig. 1A). With the recent submission of a large amount of new
mutations from several thousand individuals by exome and whole
genome sequencing projects, four of these five mutations are now
also present in dbSNP [36,49]. Our study thus confirms the
presence of the mutations referred to as rs56105247 (at Pro33),
rs56085217 (Arg45), rs78098302 (Gly126), and rs137911238
(Pro236) in the Norwegian population.
By the second approach, we detected another twelve non-
synonymous mutations (Table 4), of which the majority has been
submitted within the last year. Among the mutations that were
known at the initiation of this study, two were selected for further
investigations. Firstly, the mutation rs35635531, resulting in a
switch of Ser263 to Cys, is the only mutation that has been
submitted by three independent projects. Although the frequency
of this mutation has not been determined in detail, it is likely to be
relatively common in at least some human populations. Secondly,
the mutation causing the Gly186Val mutation was considered
particularly intriguing since this residue is located in the Mg
2+
positioning loop close to ATP and Mg
2+ in the active site cleft of
Ca (Fig. 1B) and is part of the highly conserved DFG motif
[26,50,51]. The positions of the four investigated mutations
resulting in amino acid switches are shown relative to exon
encoded sequence in Fig. 1A and in the 3D structure of Ca1i n
Fig. 1B.
Mutation of Residues Ser109 and Gly186, but not Arg45
and Ser263 in Ca1 Influences Catalytic Activity
We first tested if any of the mutations influenced the catalytic
activity of Ca. Site-directed mutagenesis was used to introduce the
required amino acid switches Arg45Gln, Ser109Pro, Gly186Val,
and Ser263Cys to Ca encoding expression vectors. Wild type
(WT) and the four mutated Ca1 products (collectively termed
Ca1Mut) were expressed in HEK-293T cells, and 20 h post
transfection the cells were lysed. Expression of protein was first
assessed by immunoblotting with a pan C antibody, revealing that
both Ca1WT (Fig. 1C, lane 1) and Ca1Mut (Fig. 1C, lanes 2 to 5)
were expressed at comparable levels and with similar apparent size
as endogenous Ca1 (Fig. 1C, lane 6). We further determined their
catalytic activity in the presence of the PKA-specific substrate
Kemptide and c-
32P-ATP (Fig. 1C). In these experiments, lysates
from untransfected cells (Fig. 1C, lane 6) were included to assess
endogenous kinase activity. This demonstrated high catalytic
activity of expressed Ca1WT which was set to 100% (Fig. 1C, lane
1). According to this assay, the catalytic activities of Ca1Arg45Gln
and Ca1Ser263Cys were shown not to be significantly different from
Ca1WT. On the other hand, the activity of Ca1Ser109Pro was
significantly lower compared to Ca1WT (P ,0.05), and the activity
of Ca1Gly186Val was comparable to background levels (Fig. 1C,
lanes 4 and 6). This suggested that mutation of Gly186 rendered
Ca inactive and prompted us to focus further on revealing the
mechanism for this inactivation. Accordingly, we transfected cells
with Ca1Gly186Val and Ca1WT and compared catalytic activity in
the absence and presence of cAMP and the PKA-specific inhibitor
PKI and compared phosphotransferase activities to mock
transfected cells (Fig. 2A). The activity of Ca1WT was reduced to
background level in the presence of PKI while activities of
Ca1Gly186Val were comparable to background levels independently
of stimulation with cAMP or inhibition with PKI (Fig. 2A, Mock
compared to Ca1Gly186Val).
To determine if CaGly186Val was completely inactive we next
expressed and purified recombinant CaWT and CaGly186Val.W e
used recombinant WT and mutated Ca2 since Ca2 is more easily
produced than Ca1 due to higher solubility [41]. Ca2 will
therefore give a higher protein yield. Ca1 and Ca2 may also be
interchanged in these experiments because studies suggest that
they are kinetically indistinguishable [41]. WT and mutated
recombinant Ca2( C a2WT and Ca2Gly186Val) were produced in
BL21(DE3) cells, purified and visualized by SDS-PAGE (Fig. 2B).
(In order to simplify the nomenclature we refer to the mutations
according to their Ca1 numbering also when introduced to Ca2.
The actual position of the mutated residues in the Ca2 protein is
Novel Mutations in the Gene Encoding Calpha of PKA
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by running protein extracts over an RIIaGly337Glu affinity column
and Ca2 bound to RIIa was eluted with 10 mM cAMP (see
Material and Methods). The purification process was evaluated
after each step by SDS-PAGE analysis (Fig. 2B, lanes 1 to 14).
Purified Ca2Gly186Val and Ca2WT were tested for catalytic activity
employing the Cook assay [22] that showed a specific activity for
Ca2WT at 20.9 6 2.1 U/mg (95% confidence interval) (Fig. 2C,
Ca2WT). In comparison, catalytic activity by Ca2Gly186Val was
undetectable demonstrating that a Gly186 to Val mutation renders
the kinase catalytically inactive (95% confidence interval of
Ca2Gly186Val: 0.55 6 0.96 U/mg) (Fig. 2C, Ca2Gly186Val).
Mutation Gly186Val Alters the Catalytic Core of Ca1
We next investigated the Gly186Val mutation in a 3D structure
model of Ca1 in an attempt to understand the molecular nature of
the kinetic inactivity (Fig. 3). Figure 3A shows selected conserved
motifs surrounding the DFG motif where residue 186 is located.
The chain of interactions leading into the DFG motif from
phosphorylated Thr197 is depicted. In the active conformation of
Ca1WT, the C- and R-spines are assembled and the structure is
optimized for catalysis (Fig. 3B). Simulated mutagenesis of
Gly186Val revealed three possible rotamers. For representation
in the figures, the rotamer with the least steric hindrance was
selected. Our Ca1Gly186Val model suggests an altered conforma-
tion of the DFG motif, which we hypothesize may disturb the
structure of the spines (Fig. 3B, lower right box). In all published
experimental structures of catalytically active kinases, there is a
conserved hydrogen bond between the side chain of Asp184 and
the amide group of Gly186 [50] (Fig. 3C, left panel, dashed line). In
figure 3C (right panel) it is shown that the presence of the
hydrophobic Val side chain leads to steric hindrance and an
unfavourable binding of the cation Mn1 (Cc1-Mn1 distance
2.7 A ˚) compared to Gly (Ca-Mn1 distance 4.3 A ˚). The simulated
distances between Cc1, Cc2 and Mn1 as well as ATP for this
rotamer and the two other rotamers of Ca1Gly186Val were reduced
(results not shown). According to these data we hypothesize that by
replacing Gly186 with Val, the bulky side chain of Val will make it
less likely for Ca to bind Mg1/Mn1 in its optimal position. This
will also prevent ATP binding, together suggesting why Ca2-
Gly186Val lacks kinase activity.
A recent study on the Raf kinase where Gly596, which is the
counterpart of Gly186 in Ca1, was mutated to Arg revealed that
some RafGly569Arg kinase activity was achieved at high concentra-
tions of ATP [52]. Based on this study and considering the
molecular structure depicted in figure 3 we speculated if increasing
the concentrations of ATP and/or Mg
2+ would be sufficient to
restore at least some kinase activity in Ca2Gly186Val. Kinase activity
of purified Ca2Gly186Val and Ca1WT were measured against
increasing doses of Mg
2+ and ATP, keeping either the ATP or
Mg
2+ concentration constant at 143 mM or 14.3 mM, respectively.
For Ca1WT high phosphotransferase activity was detected at
concentrations of Mg
2+ between 0.2 and 100 mM and ATP-
concentrations between 1 and 143 mM. At none of these
concentrations was activity of Ca2Gly186Val detectable.
Ca2Gly186Val Associates with RIIa but not RIa
Ca2Gly186Val was purified by affinity chromatography with RIIa
in which CaGly186Val was released by addition of cAMP. This
suggests that mutation of Ca1 at residue 186 does not interfere
with RII association or cAMP activation. However, ATP is
required for association between C and RI [53,54] and given the
fact that Ca2Gly186Val probably does not bind ATP efficiently, it
may be suggested that CaGly186Val will only associate with RII and
not RI. To investigate this we determined the binding of
Ca1Gly186Val to RIa and RIIa using a Bioluminescence resonance
energy transfer (BRET) assay. In these experiments, holoenzyme
formation was investigated for all four CaMut proteins to test if any
of the mutations would influence R subunit binding and cAMP
sensitivity. COS-7 cells were cotransfected with either Ca1WT or
Ca1Mut N-terminally coupled to Green Fluorescent Protein (GFP),
GFP-Ca1WT and GFP-Ca1Mut, respectively, and RIa and RIIa
C-terminally coupled to Renilla luciferase (Rluc),RIa-Rluc and
RIIa-Rluc, respectively. Immunoblotting shows the expression of
both GFP-Ca1WT and GFP-Ca1Mut (Fig. 4A, lanes 2 to 6).
Figure 4, lane 1 depicts the expression of endogenous C subunit in
cells transfected with Rluc alone serving as background. In the
case of holoenzyme formation with RIa subunits, measurements
were normalized by setting the BRET signal in holoenzyme with
GFP-Ca1WT to 100% (Fig. 4B, WT ‘‘2’’). Increasing the
intracellular concentration of cAMP with forskolin (fsk) and
IBMX (‘‘+’’) leads to the dissociation of the holoenzyme complex
and the reduction of the BRET signal by approximately 50% as
reported previously [55]. The same was true for holoenzymes
formed with RIa-Rluc and GFP-Ca1Arg45Gln, GFP-Ca1Ser109Pro,
and GFP-Ca1Ser263Cys, respectively (Fig. 4B, ‘‘+’’). In contrast, the
GFP-Ca1Gly186Val showed only residual binding to RIa in resting
cells (Fig. 4B, Gly186Val ‘‘2’’), and only marginal activation was
detected after stimulation with fsk and IBMX (Fig. 4B, Gly186Val
‘‘+’’).
Analogous to RIa-Rluc measurements with RIIa-Rluc were
performed setting unstimulated WT holoenzyme to 100% (Fig. 4C,
Table 3. Mutations in the PRKACA gene discovered by sequencing of 498 Norwegian subjects.
Exon no. Nucleotide (nt) no. Amino acid (aa) WT/mut nt WT/mut aa
No. affected
individuals Functional consequence prediction
2 102 Pro33 C/T Silent 10 Likely neutral
3 137 Arg45 G/A Arg/Gln 1 Arg45 is highly conserved in metazoan Ca/
Cb homologs – likely functional
consequences
4 328 Ser109 T/C Ser/Pro 2 Ser109 in conserved in Ca, but not in Cb –
effect unknown
5 381 Gly126 G/A Silent 3 Likely neutral
8 711 Pro236 G/A Silent 1 Likely neutral
Nucleotide enumeration is counted from the PKA Ca1 transcript start codon. Amino acid numbering is given for the mature protein with N-terminal Gly1 corresponding
to codon 2. Sequence conservation is illustrated in Supplementary Fig. S1.
doi:10.1371/journal.pone.0034838.t003
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34838Figure 1. Sequences of human wild type PKA Ca1/Ca2, location of point mutations, and activities of mutant proteins. A. The human
Ca wild type and mutated amino acid sequence. The N-terminal methionine of Ca1 is removed post-translationally, and glycine residue 1 in mature
Ca1 corresponds to codon 2. Alternating black and blue coloring shows the contribution of the eleven exons to the mature translated protein. The
codons for Val15 and Ser139 (red) are encoded by nucleotides from neighboring exons. The PRKACA gene encodes two splice variants, Ca1 and Ca2
(UniProt [59] accession number P17612), which differs by alternative use of exons 1–1 or 1–2, respectively. The four point mutations are highlighted
and denoted with the amino acid change. The Gly186Val mutation is located in the DFG motif (boxed) [26]. B. The location of the four mutations are
indicated (red) in a model of Ca1 based on the PDB structure 3FJQ [48]. Residues are designated according to the WT Ca1 sequence. ATP and two
divalent cations are shown in yellow. C. Immunoblotting and phosphotransferase assays of WT and mutated Ca1 subunits. Ca1 was expressed in HEK
293T cells and immunoreactive C subunit detected with anti-C (Anti-mouse PKA[C], cat. no. 610981) after separation of cell extracts by SDS-PAGE in
10% gels and immunoblotting. Expression of Ca1WT is shown in lane 1 (WT), mutated Ca1 in lanes 2 to 5, and endogenous Ca1 in lane 6 (Mock).
Activities are normalized relative to Ca1WT activity. Data represents mean values 6 standard deviation (SD) of triplicate experiments (*, P , 0.05. **, P
, 0.005).
doi:10.1371/journal.pone.0034838.g001
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GFP-CaMut dissociate almost completely resulting in a stronger
BRET signal reduction (Fig. 4C, ‘‘+’’). Interestingly, whereas GFP-
Ca1Gly186Val does not stably interact with RIa-Rluc, the
holoenzymes formed with RIIa-Rluc shows a comparable
magnitude to GFP-Ca1WT (Fig. 4C, Gly186Val ‘‘2’’ and WT
‘‘2’’).
Discussion
Here we have examined the human PRKACA gene for
mutations by sequencing genomic DNA from 498 Norwegian
individuals and by searching for earlier reported mutations in
publicly available databases. By genomic sequencing, we identified
two nucleotide changes that resulted in the mutations Arg45Gln
and Ser109Pro in the Ca1 protein. In public databases we
identified two interesting mutations that would lead to residue
switches, Gly186Val and Ser263Cys.
Two out of the four mutations (Ca1Ser109Pro and Ca1Gly186Val)
resulted in significantly reduced kinase activity. It should, however,
be noted that comparing the exact activities of Ca1WT and
Ca1Mut was a challenge due to differences in transfection
efficiencies. We compensated for this by adjusting activities to
immunoreactivity in the immunoblots. This demonstrated reduced
kinase activity for Ca1Ser109Pro, whereas Ca1Gly186Val was kinase
inactive. As Gly186 is absolutely conserved (Supplementary Fig. S1)
and is part of the DFG motif [27] we investigated the mutation
affecting this residue in more detail. The importance of Gly186
conservation was underscored since mutation was associated with
complete abrogation of kinase activity. The exact mechanism that
leads to complete inactivation in this case is not known. However,
CaGly186Val was successfully purified by RIIa-affinity chromatog-
raphy followed by elution with cAMP. This, together with the fact
that CaGly186Val forms cAMP-sensitive holoenzymes with RIIa
in vivo suggests that lack of enzymatic activity is not caused by an
overall misfolding of the protein. We rather suggest that lack of
kinase activity is due to less extensive molecular changes, affecting
only parts of the protein structure. The introduction of a bulky
residue in place of Gly186 is likely to affect many critical factors
necessary for kinase activity. The most apparent explanation is
that the aliphatic Val186 side chain leads to less efficient binding of
Mg1/Mn1 due to displacement of the cation itself or water
molecules that are solvating Mg1/Mn1. Loss of Mg1/Mn1 would
in turn disable ATP binding, thus explaining the kinase inactivity.
This hypothesis is supported by our BRET results, which show
exclusive binding to RII but not RI subunits. Moreover, we were
unable to purify CaGly186Val using PKI affinity chromatography
(results not shown). It has previously been shown that the RI
subunits, as well as PKI, need ATP to bind C with high affinity
[53,54].
According to our model, it is not unlikely that the hydrogen
bond between residues 184 and 186 fails to form in CaGly186Val,
leading to displacement of Asp184 and inability to position Mg1 or
Mn1 and thereby ATP in the active site. The inability to bind
ATP implicates that the C-spine is not established, which is
necessary for the active conformation. An alternative explanation
for the inactivity is that Val186, instead of suppressing binding of
Mg1/Mn1 and ATP, is rather displaced, leading to a conforma-
tional change in the DFG motif itself. This would lead to a
malformed R-spine, which is also thought to be incompatible with
kinase activity [26].
Table 4. Additional nonsynonymous mutations in the PRKACA gene found in public databases.
dbSNP Exon no. Nucleotide no. Amino acid WT/mut nt WT/mut aa Functional consequence prediction
rs142045517 2 103 Ala34 G/A Ala/Thr Ala34 is Ser in rodent Ca and Thr in human Cb
– likely few functional consequences
rs56029020 3 121 Leu40 T/G Leu/Val Leu40 is absolutely conserved in metazoan Ca/
Cb homologs – likely deleterious
rs112360106 3 149 Leu49 T/A Leu/His Conserved in metazoan Ca/Cb homologs –
likely deleterious
rs148280386 5 409 Gly136 G/A Gly/Arg Conserved in metazoan Ca/Cb homologs –
likely deleterious
rs142007512 6 541 Ile180 A/G Ile/Val Highly conserved in vertebrate Ca/Cb –
possibly functional effects
rs11541563 7 560 Gly186 G/T Gly/Val Conserved in metazoan Ca/Cb homologs –
likely deleterious
rs34988264 8 673 Leu224 -/G, 1 nt insertion Frame shift in exon 8 – very likely results in
nonfunctional Ca
rs35635531 9 791 Ser263 C/G Ser/Cys Highly conserved in metazoan Ca/Cb
homologs – possibly functional effects
rs146946205 9 842 Arg280 G/A Arg/His Conserved in metazoan Ca/Cb homologs –
likely deleterious
rs187770246 9 926 Arg308 G/A Arg/Lys Conserved as Arg or Lys in metazoa – likely
few consequences
rs149832080 10 955 Phe318 T/C Phe/Leu Not conserved in vertebrates – likely few
consequences
rs141087932 10 1045 Ser348 T/C Ser/Pro Not conserved in mammals – likely few
consequences
Enumeration is given as in Table 3, and sequence conservation is illustrated in Supplementary Fig. S1. Reference identifiers from dbSNP [36,49] are included in the left
column.
doi:10.1371/journal.pone.0034838.t004
Novel Mutations in the Gene Encoding Calpha of PKA
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34838Reduced kinase activity was also observed for Ca1Ser109Pro.
Ser109 is located in the middle of b-strand 4 in the small lobe and
this b-strand stabilizes the N-terminal end through targeting Ser109
to Thr37 [48]. It is well known that the N-terminal tail is important
for C subunit stability, and deletion of the N-terminus has
previously been demonstrated to lead to a significant reduction in
thermal stability [56]. We speculate that mutation of Ser109 to Pro
leads to partial loss of N terminal structure and destabilization of
the kinase, and that this may in part provide an explanation for the
reduced kinase activity. A second consequence of mutating Ser109
may be associated with our recent findings that Ser109 belongs to a
series of signature residues that can be used to distinguish the Ca
from Cb ortholog (unpublished results). Due to this, the Ser109Pro
mutation may result in alteration of Ca-specific functions which do
not include holoenzyme formation since our BRET-results showed
that Ca1Ser109Pro formed holoenzymes with both RIa and RIIa
with comparable affinities as the Ca1WT. Full comprehension of
the reduced kinase activity and other features associated with
mutation at Ser109 merits further investigation.
Neither mutations of Arg45Gln nor Ser263Cys influenced
apparent kinase activity. Arg45 is located near a recently identified
conserved pocket in the N lobe known as the N lobe cap, which is
above the crucial amino acids Ala70 and Lys72 [48]. Ala70 is part of
the C-spine while Lys72 is directly involved in ATP binding. It
might have been expected that mutation of Arg45 would affect
kinase activity, also because this residue is highly conserved in
metazoan PKA Ca/Cb homologs (Supplementary Fig. S1) and is
clearly under strong purifying selection. The fact that we did not
observe any change in phosphotransferase activity suggests that
the mutation does not influence the positioning of Ala70 and Lys72.
Despite of this, it may be that mutation of residue 45 affects other
features necessary for function of the kinase. It could be speculated
that the N lobe cap may also be a docking site for proteins
inhibiting kinase activity by disturbing either the C-spine or Lys72.
This may indicate that the Arg45Gln mutation could be involved
in deregulated PKA activity due to altered interactions with so far
unidentified interaction partners docking to the N lobe cap. This
binding partner does not include the R subunit since the BRET
experiments of Ca1Arg45Gln showed no differences in binding and
Figure 2. Activity of wild type and Gly186Val mutated Ca1 and Ca2. A. Phosphotransferase activity of Ca1WT and Ca1Gly186Val expressed in
HEK-293T cells was measured in the presence of Kemptide and c-
32P-ATP, and in the presence (+) and absence (2) of cAMP or PKI kinase inhibitor.
Enzyme activity was normalized according to activity of Ca1WT which was set to 100%. The data are presented as mean values 6 SD of triplicate
experiments. B. Recombinant Ca2WT (not shown) and Ca2Gly186Val were expressed in BL21 (DE3) cells. For Ca2Gly186Val, expressed protein was purified
by running cell extracts over a Ni-resin loaded with His6RIIaGly337Glu affinity column and eluted with 10 mM cAMP. The purification steps of
Ca2Gly186Val are shown after separation of the various fractions by SDS-PAGE. The crude cell extract (lane 1, crude) was centrifuged and divided into a
soluble (lane 2) and an insoluble fraction (lane 3, pellet). Proteins not retained on the column is shown (lane 5, Flowthrough). W1, W3, W4 and W5
(lanes 6 and 8–10) depict protein contents of successive washing steps using buffer containing 50 mM NaH2PO4 (pH 8.0), 5 mM b-mercaptoethanol,
and 25 mM KCl. E1-E4 (lanes 11–14 ) depict protein content in consecutive elution fractions using buffer containing 50 mM NaH2PO4 (pH 8,0), 10 mM
cAMP, 5 mM b-mercaptoethanol, and 25 mM KCl. To assure equal amounts of RIIaGly337Glu and Ca2Gly186Val, cell extracts of RIIaGly337Glu and
Ca2Gly186Val expressed in separate bacteria cultures were mixed 1:1 (lane 7, 1:1 mix). Protein with the correct molecular mass (arrow to the right) was
obtained in fractions E1–E3. Ten ml was applied in lanes 6, 8, 9 and 10, seven ml in lane 1, 2, 3, 5 and 7, and five ml in lane 4. (Molecular Weight Marker
(MWM)). C. Kinase activity of recombinant Ca2WT and Ca2Gly186Val was determined by employing the spectrophotometric Cook assay. The data are
presented as mean values 6 SD of triplicate experiments.
doi:10.1371/journal.pone.0034838.g002
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compared to Ca1WT. This is also consistent with the localization of
Arg45 far from the R subunit docking site.
Ser263 is highly conserved among metazoa (Supplementary Fig.
S1) and is part of the H helix at the very lower end of the large
lobe. This site is close to the R subunit docking sites, and the
Figure 3. Mutation of Gly186 in Ca1 prevents Ca from binding ATP and divalent cations. A. The 3D structure of the catalytic site of Ca1.
Selected conserved motifs and their relations to divalent cations Mn1 and Mn2 and ATP are shown. Residues connecting phospho-Thr197 (pThr197)t o
the DFG motif are represented as stick models [50]. Mn2ATP (green), the DFG motif (teal), Gly-rich loop (salmon), catalytic loop (yellow), and activation
loop (purple) are also highlighted. B. Overall structure of Ca1WT with the conserved structural motifs the C- and R-spine structural motifs highlighted.
The boxed segments depict spatial relations between residue 186 (Gly or Val) and ATP, divalent cations, and the C- and R-spines. C. DFG motif in
Ca1WT (left) and Ca1Gly186Val (right) and its relations to Mn1 and ATP. Residues are represented as stick models with carbon (orange), oxygen (red) and
nitrogen (blue) atoms. The hydrogen bond between the side chain of Asp184 and the amide group of Gly186 (dashed line) is predicted to be broken in
Ca1Gly186Val due to the Val side chain. The models are based on the structure with PDB identifier 3FJQ [48].
doi:10.1371/journal.pone.0034838.g003
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activity as was also demonstrated here. Rather it could be
speculated that a shift from Ser to Cys could influence the
mechanism regulating R-C interaction in vivo. However, our
BRET experiments showed no difference in holoenzyme forma-
tion and dissociation of Ca1Ser263Cys to neither RIa nor RIIa
subunits compared to Ca1WT. Although no effect of a Ser263Cys
mutation in Ca was detected, the high degree of conservation of
this residue and strong purifying selection is an indicator of a
hereto unknown functional importance of Ser263.
Among the mutations identified in the sequencing of the
PRKACA gene, Arg45Gln and Ser109Pro were identified in one
and two samples, respectively. Of the two mutations identified in
the database search only the Ser263Cys mutation was identified
by two independent submitters. To what extent this indicates
anything about the prevalence of the different mutations, remains
to be verified. However, Gly in the DFG motif is a relatively
frequent site of disease-causing mutation in various protein
kinases which is most likely due to kinase inactivation [57]. As
described above, homozygote targeting mutation of the PRKACA
gene in mouse is associated with high pre- and postnatal lethality,
most probably due to lack of kinase activity at critical steps in
embryonic development [30,32]. Based on this, it is expected
that any mutation affecting Ca activity may lead to a severe
phenotype and possibly disease in human. Since the Ca1Gly186Val
mutation resulted in catalytic inactivation and partial lack of
holoenzyme formation, homozygote mutation for Gly186 in vivo
may functionally be considered a gene KO and hence may be
incompatible with normal development and life. The same would
most likely be the case for the frame shift mutation detected in
exon 8. The fact that CaGly186Val exclusively forms holoenzyme
with RII subunits suggest that individuals with heterozygote
mutation of Gly186 may have reduced levels of PKA type I
holoenzymes, in addition to harboring type II holoenzymes
occupied by inactive C subunits, which can hypothetically cause
an unbalance in PKA signaling.
The other investigated mutations are likely more compatible
with normal development and may not be associated with disease
since neither of them influenced holoenzyme formation and
mutation of Ser109 only partly reduced catalytic activity. Despite
this there is a possibility that homozygote mutation of Ser109 may
be associated with disease since experiments on mice have
demonstrated that reduced C subunit gene expression can lead
to spinal neural tube defects [33]. In total, 13 nonsynonymous
point mutations in the PRKACA gene were identified in the present
study. For example the Gly186Val mutation was only identified in
a single EST sequence, and no frequency data was available.
Hence, the information on the prevalence of the various mutations
is therefore limited and a full comprehension of their existence in
patients or patient groups remains to be elucidated. Finally, it is
also worth mentioning that several thousand regions of the human
genome have structural variation in large segments termed Copy
Number Variation (CNV) [58]. In this paper they report that three
out of 95 individuals were found to have a loss of ,160 kb which
included the whole PRKACA gene as well as up- and downstream
genes. Due to this it may be speculated that a combination of
CNV deletion at the PRKACA locus and a heterozygote loss-of-
function mutation of Ca could be associated with disease due to
severe reduction in C subunit gene dose. To what extent this is a
cause of disease remains to be determined.
Figure 4. Assessment of PKA type I and II holoenzyme
formation and dissociation with CaWT and CaMut applying
BRET in living cells. Co-expression of GFP-Ca1WT or GFP-Ca1Mut with
wt RIa and RIIa subunits fused to Renilla luciferase (RIa-Rluc, RIIa-Rluc,
as described in Diskar et al [55] and Material and Methods). A. Western
blot analysis of COS-7 cells expressing either Renilla luciferase alone
(lane 1), or R-Rluc plus GFP-Ca1WT (lane 6) and GFP-Ca1Mut (lanes 2–5).
Molecular mass and C subunit identity is shown at the left and right,
respectively. B. Analysis of PKA type I holoenzyme formation (RIa-Rluc)
with GFP-Ca1WT or GFP-Ca1Mut. Expression of Rluc alone defines the
background signal (lane 1). 48 h post transfection the luciferase
substrate was added and light emission from GFP
2 and luciferase was
monitored in the absence (2) or presence (+)o f5 0mM forskolin (fsk)
and 100 mM IBMX (+). The results are shown as mean values 6 SEM of 3
experiments. C. Analysis of PKA type II holoenzyme formation (RIIa-Rluc)
was done as described for PKA type I in panel B.
doi:10.1371/journal.pone.0034838.g004
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Figure S1 Multiple sequence alignment of human PKA Ca (top
row) and homologous sequences from a number of metazoan
species for the sequence segments containing the 13 mutations
discussed in the present study. Enumeration is according to the
human PKA Ca1 splice variant and the mutated residues are
highlighted. The sequences were obtained from the NCBI (http://
www.ncbi.nlm.nih.gov) and UniProt (http://www.uniprot.org)
protein sequence databases with the following identifiers:
P17612, P05132, P00517, NP_001003032, Q90WN3, A3KMS9,
NP_001003470, P22694, P68181, P05131, XP_867543,
XP_422379, Q7ZWV0, Q3ZB92, Q7T374, XP_001175934,
XP_002740161, CAG44453, XP_393285, XP_968170,
NP_476977.
(TIF)
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